Press releases
- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
- KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
- KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
- KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
- KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
More ▼
Key statistics
As of last trade, Kalvista Pharmaceuticals Inc (4XC1:FRA) traded at 9.60, 39.13% above the 52 week low of 6.90 set on Nov 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.60 |
---|---|
High | 9.60 |
Low | 9.60 |
Bid | 9.55 |
Offer | 10.20 |
Previous close | 9.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 42.19m |
Free float | 41.71m |
P/E (TTM) | -- |
Market cap | 442.56m USD |
EPS (TTM) | -3.14 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:13 BST.
More ▼